2010 Patients Prescription 
pharmaphorum
JANUARY 12, 2023
As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Drug diversion is the channelling of prescription drugs from a medical source into the illegal market.
World of DTC Marketing
DECEMBER 13, 2021
OPENING: American cancer patients spent more than $21 billion on their care in 2019. billion and patient time costs of $4.87 Some cancer patients may face out-of-pocket costs of nearly $12,000 a year for one drug. Many cancer patients without adequate insurance have only the starkest choice: your money or your life.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
APRIL 7, 2021
I have to laugh when I hear that a pharma company is patient-centric because that’s become a slogan to make employees feel good about themselves while the costs of prescription drugs increase every year. Food and Drug Administration between 2010 and 2016 yet did taxpayers receive any discount?
Pharmaceutical Technology
JUNE 12, 2023
A leading CB2 agonist, olorinab, displayed encouraging results when managing abdominal pain in irritable bowel syndrome (IBS) patients, but failed to meet the primary efficacy endpoints. Currently, Jazz Pharmaceuticals’s nabiximols is the only cannabinoid approved for pain, receiving approval in Israel, in August 2010.
PM360
MAY 15, 2023
After a developmental day of shadowing a pharma sales rep, the fire was lite and she joined the sales team never looking back, ultimately landing her a role at ConnectiveRx in 2010. Laura has educated the new ConnectiveRx employees on the “real” patient journey. Interestingly, her approach was not only shaped by professional aptitude.
Pharmaceutical Technology
JUNE 29, 2022
Others judge its success based on the fact that 95% of rare diseases still have no available therapies and patient needs remain unmet. However, extended market exclusivity is often associated with high drug pricing and limited patient access. of the total patient population suffering from rare diseases. Approximately 10.9%
PM360
FEBRUARY 1, 2024
The landscape is highly competitive with new prescription medications launching worldwide each year. Key stumbling blocks include payer activation and reimbursement hurdles, regulatory complexities, tepid market adoption by healthcare professionals (HCPs), field force inefficiencies, and obstacles in engaging and adopting patients.
Expert insights. Personalized for you.
105 
Let's personalize your content